Why I Recommend SGLT2 Inhibitors for Renal Protection in Patients With T2D
  • CME

Pivotal SGLT2 inhibitor study results demonstrate renoprotective effects in patients with T2D, with and without established chronic kidney disease.
Richard E. Pratley, MD
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: June 21, 2021 Expiration: June 20, 2022

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Summarize pivotal SGLT2-I study results that demonstrate renoprotective effects in patients with T2D, with and without established chronic kidney disease


Supported by an educational grant from

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine 
Orlando, Florida

Richard E. Pratley, MD, has disclosed that he has received consulting fees from Corcept Therapeutics, Merck, Novo Nordisk, Pfizer, Sanofi, Scohia, and Sun Pharmaceutical; funds for research support from Hanmi, Metavention, Novo Nordisk, Poxel, and Sanofi; and fees for non-CME/CE services from Novo Nordisk.


Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Petra Cravens, PhD

Editorial Contributor

Petra Cravens, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Ruth Cohen Cooper, CHCP

Vice President, Science and Strategy

Ruth Cohen Cooper, CHCP, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for endocrinologists, primary care clinicians (including MDs, DOs, NPs, and PAs), and other healthcare professionals who are part of the care team involved in the medical management of patients with T2D.


The goal of this initiative is to provide expert perspectives about current issues and strategies related to T2D management to help clinicians integrate these practice-changing advances into patient care.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 21, 2021, through June 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on improving care for type 2 diabetes

Carol Hatch Wysham, MD Released: October 7, 2021

Downloadable slides from Clinical Care Options (CCO) featuring expert insights on individualizing management of patients with T2D and cardiometabolic comorbidities

Carol Hatch Wysham, MD Released: September 30, 2021

Short video from Clinical Care Options (CCO) featuring expert insights on the clinical management of persons with T2D and metabolic comorbidities

Carol Hatch Wysham, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Registered Dieticians/Dietetic Technicians, Registered: maximum of 0.5 CPEU(s) Released: September 30, 2021 Expired: September 29, 2022

From Dr. Carol Hatch Wysham and Clinical Care Options (CCO), expert commentary on emerging data on tirzepatide for type 2 diabetes

Carol Hatch Wysham, MD Released: September 21, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.